Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

Friedrich, M, Jasinski-Bergner, S, Lazaridou, M-F, Subbarayan, K, Massa, C, Tretbar, S, Mueller, A, Handke, D, Biehl, K, Bukur, J, Donia, M, Mandelboim, O & Seliger, B 2019, 'Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy' Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-019-02373-1

APA

Friedrich, M., Jasinski-Bergner, S., Lazaridou, M-F., Subbarayan, K., Massa, C., Tretbar, S., ... Seliger, B. (2019). Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-019-02373-1

CBE

Friedrich M, Jasinski-Bergner S, Lazaridou M-F, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, Donia M, Mandelboim O, Seliger B. 2019. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-019-02373-1

MLA

Vancouver

Author

Friedrich, Michael ; Jasinski-Bergner, Simon ; Lazaridou, Maria-Filothei ; Subbarayan, Karthikeyan ; Massa, Chiara ; Tretbar, Sandy ; Mueller, Anja ; Handke, Diana ; Biehl, Katharina ; Bukur, Jürgen ; Donia, Marco ; Mandelboim, Ofer ; Seliger, Barbara. / Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. I: Cancer immunology, immunotherapy : CII. 2019.

Bibtex

@article{bd965a96ae6d45c2b9e00d5277176722,
title = "Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy",
abstract = "Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.",
author = "Michael Friedrich and Simon Jasinski-Bergner and Maria-Filothei Lazaridou and Karthikeyan Subbarayan and Chiara Massa and Sandy Tretbar and Anja Mueller and Diana Handke and Katharina Biehl and J{\"u}rgen Bukur and Marco Donia and Ofer Mandelboim and Barbara Seliger",
year = "2019",
month = "8",
day = "3",
doi = "10.1007/s00262-019-02373-1",
language = "English",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

AU - Friedrich, Michael

AU - Jasinski-Bergner, Simon

AU - Lazaridou, Maria-Filothei

AU - Subbarayan, Karthikeyan

AU - Massa, Chiara

AU - Tretbar, Sandy

AU - Mueller, Anja

AU - Handke, Diana

AU - Biehl, Katharina

AU - Bukur, Jürgen

AU - Donia, Marco

AU - Mandelboim, Ofer

AU - Seliger, Barbara

PY - 2019/8/3

Y1 - 2019/8/3

N2 - Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.

AB - Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.

U2 - 10.1007/s00262-019-02373-1

DO - 10.1007/s00262-019-02373-1

M3 - Review

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

ER -

ID: 57730672